Press Releases

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology RUTHERFORD, N.J., Feb. 26, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP,…

Rutherford, NJ., Feb. 04, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the pricing of a “best efforts” public offering of approximately 2.6 million shares of common stock. The offering price of each share of common stock is…

The study met its primary endpoint with no procedure or device related serious adverse events reported RUTHERFORD, N.J., Feb. 04, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the successful completion of its first…

1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025 RUTHERFORD, N.J., Jan. 30, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect…

ISO Certification highlights commitment to quality for continuous blood glucose monitor RUTHERFORD, N.J., Jan. 21, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has received ISO 13485:2016 certification from the British…

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes RUTHERFORD, N.J., Jan. 15, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that…

Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes RUTHERFORD, N.J., Jan. 07, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it is presenting…

Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8 weeks Rutherford, NJ, Dec. 03, 2024 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, has announced…

Rutherford, NJ., Nov. 14, 2024 — Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the closing of a “best efforts” public offering of 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share of common stock and each…

Rutherford, NJ., Nov. 13, 2024 — Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the launch of a “best efforts” public offering of approximately 7,195,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common…